Atlas Trials

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

Clinical trial NCT05163249 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05163249
Sponsor
Guangdong Association of Clinical Trials
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Carcinoma, Non-Small-Cell Lung
Start date
2022-05-31
Primary completion
2024-04-01
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.